These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8096383)

  • 21. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
    Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV
    Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
    Lee MT; Liebow C; Kamer AR; Schally AV
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
    Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
    Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
    Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
    Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of somatostatin analogues on proliferation of murine colonic cancer cells in vitro.
    Pawlikowski M; Kunert-Radek J; Winczyk K
    Cytobios; 1997; 89(358-359):183-7. PubMed ID: 9418016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs.
    Woltering EA; O'Dorisio MS; Murphy WA; Chen F; Drouant GJ; Espenan GD; Fisher DR; Sharma C; Diaco DS; Maloney TM; Fuselier JA; Nelson JA; O'Dorisio TM; Coy DH
    J Pept Res; 1999 Feb; 53(2):201-13. PubMed ID: 10195457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs.
    Murphy WA; Meyers CA; Coy DH
    Endocrinology; 1981 Aug; 109(2):491-5. PubMed ID: 6113951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiproliferative effect of somatostatin and analogs.
    Bousquet C; Puente E; Buscail L; Vaysse N; Susini C
    Chemotherapy; 2001; 47 Suppl 2():30-9. PubMed ID: 11275700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
    Liebow C; Reilly C; Serrano M; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(6):2003-7. PubMed ID: 2564678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
    Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160.
    Yano T; Radulovic S; Osuga Y; Kugu K; Yoshikawa H; Taketani Y; Schally AV
    Oncology; 2000; 59 Suppl 1():45-9. PubMed ID: 11096356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.
    Benali N; Cordelier P; Calise D; Pages P; Rochaix P; Nagy A; Esteve JP; Pour PM; Schally AV; Vaysse N; Susini C; Buscail L
    Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9180-5. PubMed ID: 10900262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New cyclic somatostatin analogues containing a pyrazinone ring: importance of Tyr for antiproliferative activity.
    Miyazaki A; Tsuda Y; Fukushima S; Yokoi T; Vántus T; Bökönyi G; Szabó E; Horváth A; Kéri G; Okada Y
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6199-201. PubMed ID: 18930401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
    Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
    Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.